Autophagy Maintenance (AUTOMAIN)

This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.

Trial Details

NCT ID
NCT06971744
Phase
PHASE2
Sponsor
Medical University of South Carolina
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Hydroxychloroquine
  • Nelfinavir
  • Bevacizumab
Locations (sample)
  • Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

  • Participants must have platinum-sensitive first recurrent high-grade serous or high-grade predominantly serous ovarian cancer, fallopian tube cance…
  • All participants must agree to have previously undergone genetic testing with germline panel testing with at least BRCA 1/2 mutation status known a…
  • Participants must be enrolled within 3-8 weeks of the first day of the last cycle of platinum-based chemotherapy for their first cancer recurrence.…
  • Evidence of platinum-sensitive response to current platinum-based chemotherapy with a partial or complete response based on imaging or CA-125 trend

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →